Analyst Forecast Hikes After Mixed Q4 Mask Persistent Risks

What happened

Cardinal Health released mixed fourth-quarter results, with some metrics missing consensus but forward guidance strong enough to trigger analyst upgrades. The beat-and-raise cadence continued, further embedding expectation of sustained double-digit EPS growth into the stock. This outcome aligns with the crowded bullish narrative that has driven shares to premium multiples, but it also heightens vulnerability to any operational hiccup. The margin of safety remains absent at current levels, as the valuation hinges on flawless specialty and MSO execution. The mixed print underscores the growing gap between non-GAAP optimism and GAAP realities, a disconnect that could widen in an adverse policy or customer-concentration scenario.

Implication

Investors should use any post-earnings strength to reduce positions, as the stock now trades at ~22x non-GAAP EPS with no tangible book value cushion. The mixed results and subsequent analyst hikes confirm that the market is willing to overlook misses in certain areas as long as the top-line story stays intact, a classic late-cycle dynamic. With FY26 guidance raised again, the bar for FY27 is now even higher, and any disappointment could trigger a sharp de-rating. The underlying risks of customer concentration, IRA-driven margin compression, and acquisition-related non-GAAP distortion remain underappreciated in the current price. A pullback to the $185–$190 range would offer a more balanced entry, but until then, capital preservation is paramount.

Thesis delta

The mixed Q4 results and subsequent forecast increases reinforce our bearish stance; the market is rewarding inconsistent performance with higher multiples, ignoring the erosion of GAAP earnings quality. This creates an even more skewed risk/reward profile, as the next disappointment will find no valuation support. We maintain the POTENTIAL SELL rating and would lighten positions on any rally above $210.